Neuromyelitis optica (NMO) and the limited forms known as NMO spectrum disorders (NMOSD) are characterized by severe attacks of optic neuritis and/or longitudinally extensive transverse myelitis (LETM).[@b1] A significant proportion of NMOSD patients are seropositive for aquaporin-4 (AQP4) antibodies.[@b2] The primary target for these autoantibodies is the AQP4, a water channel richly expressed in the foot processes of astrocytes.[@b3] Immunoglobulin G (IgG) deposits with complement activation in perivascular areas, associated with astrocyte loss, are observed in acute NMOSD lesions.[@b4],[@b5]

We previously reported a remarkable increase in the cerebrospinal fluid (CSF) of glial fibrillary acidic protein (GFAP), an astrocyte-specific marker during NMOSD attacks.[@b6] The GFAP elevation was far more pronounced than myelin and neuronal markers, indicating that astrocytes are the primary target cells in these patients with AQP4 antibodies. Previous studies have found elevated interleukin (IL)−6 and other cytokine levels in the CSF of NMOSD patients compared to multiple sclerosis (MS) patients and controls, and that the concentration of IL-6 seems to correlate with GFAP levels.[@b7]--[@b9] However, AQP4 antibody titers in the serum did not correlate with GFAP levels in 1 study,[@b8] and no study has evaluated AQP4 antibody titers in the CSF. In this pilot study, we evaluated AQP4 antibody levels measured directly in the CSF during attacks using our highly sensitive cell-based assay (CBA) for AQP4 antibodies,[@b10] and correlated these levels with astrocyte damage and the cytokine profile.

Patients and Methods
====================

We enrolled a total of 11 consecutive NMOSD patients (10 females; 1 male) with a median age of 50 years (range = 24--71) seen at Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo (Brazil) with detectable AQP4 antibody in sera and CSF seen during 2011 and 2012---6 patients with definitive NMO who met Wingerchuk\'s 2006 revised diagnostic criteria,[@b1] and 5 NMOSD patients with LETM (3 monophasic and 2 relapsing). For simplicity, we use the term NMOSD to encompass both NMO and NMOSD. We included NMOSD cases with paired serum and CSF samples (at least 2 aliquots of 500 µl) stored at −80°C for analysis. Seven sera/CSF samples were collected during attacks (before intravenous methylprednisolone or plasmapheresis) and 4 during remission (for diagnostic purposes without signs suggestive of NMOSD attacks in the past 30 days, all receiving oral prednisone and 2 in combination with azathioprine). Samples were shipped on dry ice and stored again at −80°C until analysis.

All sera and CSF samples were analyzed at Tohoku University to detect AQP4 antibodies using a CBA with HEK-293 living cells stably transfected with the M23 isoform of AQP4 as previously described.[@b10] The AQP4 antibody titers were calculated using endpoint dilutions.

Astrocyte damage was evaluated measuring GFAP levels in the CSF with a commercially available enzyme-linked immunosorbent assay (A05188; SPI-Bio, Montigny-le-Bretonneux, France) as previously described following manufacturer\'s instructions.[@b6] In addition, we measured the following cytokine levels in the CSF: IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interferon (IFN)-γ, soluble CD40 ligand, and tumor necrosis factor-α. Cytokines were measured using a multiplexed fluorescent magnetic bead-based immunoassay (Bioplex Pro Human Th17 Cytokine Panel 15-Plex, 171-AA001M; Bio-Rad Laboratories, Hercules, CA) according to manufacturer\'s instructions. Only cytokines with detectable levels in at least one-third of the CSF samples were considered for statistical analysis.

We have compared the measurements of samples obtained during attacks and remission with Mann--Whitney *U* test, Spearman correlation coefficient rank was used to evaluate correlation between 2 variables, and 2-tailed *p* values \< 0.05 were considered significant. We considered correlations to be of interest with *r* \> 0.6. Results of measurements are shown in mean and standard deviation unless otherwise indicated.

This study was approved by the ethics committee of each center and conducted in accordance with internationally recognized ethical standards. All study participants provided written consent.

Results
=======

The serum AQP4 antibody titers were found at high levels in all patients during attacks and remission. In contrast, AQP4 antibody titers in the CSF were remarkably higher only in samples collected during attacks, as shown in the Figure. Consequently, the CSF:serum ratio found during remission (1:2,048 ± 1:1,448) was higher than during NMO attacks (1:204 ± 1:175), *p* = 0.0030, and accompanied by elevation of other CSF parameters indicative of inflammation such as pleocytosis (61 ± 88 vs 2 ± 1 cells/µl, *p* = 0.0152) and protein (74.0 ± 41.9 vs 27.0 ± 4.5mg/dl, *p* = 0.0273). Furthermore, the levels of IL-6 (1,784.97 ± 3,788.05 vs 6.42 ± 4.81pg/ml, *p* = 0.0121), IL-1β (0.35 ± 0.34 vs 0.06 ± 0.02pg/ml, *p* = 0.242), and IL-10 (1.33 ± 0.71 vs 0.77 ± 0.17pg/ml, *p* = 0.0424) were also elevated in CSF samples collected during NMO attacks compared to those collected during remission. Similarly to AQP4 antibody levels and cytokines in the CSF, the GFAP levels were remarkably elevated during attacks compared to samples collected during remission (11,578.00 ± 21,188.00 vs 2.66 ± 2.32ng/ml, *p* = 0.0242).

![Aquaporin-4 (AQP4) antibody titers in (A) the cerebrospinal fluid (CSF) and (B) serum during attacks and remission. (C) CSF AQP4 antibody titers strongly correlate with glial fibrillary acidic protein (GFAP; Spearman rho = 0.9439, *p* \< 0.0001), and (D) GFAP levels correlate with interleukin (IL)−6 (Spearman rho = 0.8091, *p* = 0.0026).](ana0076-0305-f1){#fig01}

We found a very strong correlation of CSF AQP4 antibody titers with GFAP (*r* = 0.9439, *p* \< 0.0001), cell counts (*r* = 0.7679, *p* = 0.0058), and protein levels (*r* = 0.9460, *p* \< 0.0001) in the CSF. However, there was no correlation between serum AQP4 antibody titers and any of those parameters in the CSF (GFAP, *r* = 0.1860, *p* = 0.5860; cell counts, *r* = −0.2891, *p* = 0.3886; protein *r* = 0.0532, *p* = 0.8764). Interestingly, the serum AQP4 antibody titers did not correlate with CSF AQP4 antibody titers (*r* = 0.1860, *p* = 0.5840), even if we analyze only the samples collected during attacks (*r* = 0.3397, *p* = 0.4560).

Cytokines such as IL-1β, IL-6, IL-10, and IL-31 also correlated with CSF AQP4 antibody levels, but there was no correlation with serum AQP4 antibody titers, as summarized in the Table. We also found correlation between astrocyte injury measured by GFAP levels and concentrations of IL-1β (*r* = 0.7517, *p* = 0.0076), IL-6 (*r* = 0.8091, *p* = 0.0026), IL-10 (*r* = 0.8082, *p* = 0.0026), IL-31 (*r* = 0.6986, *p* = 0.0168), and IFN-γ (*r* = 0.6391, *p* = 0.0343).

###### 

Correlations between CSF and Serum AQP4 Antibody Titers and Cytokine Levels in the CSF of NMOSD Patients (n = 11)

           CSF AQP4 Antibody Titers   Serum AQP4 Antibody Titers             
  -------- -------------------------- ---------------------------- --------- --------
  IL-1β    0.7916                     0.0037                       0.0069    0.1125
  IL-4     −0.2343                    0.4881                       −0.2140   0.9838
  IL-6     0.9054                     0.0001                       0.0970    0.7766
  IL-10    0.8321                     0.0015                       −0.1624   0.6333
  IL-17A   −0.1673                    0.6229                       −0.2408   0.4757
  IL-23    −0.4364                    0.1796                       −0.3274   0.3257
  IL-25    0.3919                     0.2333                       0.1810    0.5943
  IL-31    0.6386                     0.0345                       −0.2738   0.4152
  IFN-γ    0.5992                     0.0514                       −0.0794   0.8164
  sCD40L   0.5008                     0.1166                       −0.1986   0.5582
  TNF-α    0.5406                     0.0860                       −0.3936   0.2311

AQP4 = aquaporin-4; CSF = cerebrospinal fluid; IFN = interferon; IL = interleukin; NMOSD = neuromyelitis optica spectrum disorders; sCD40L = soluble CD40 ligand; TNF = tumor necrosis factor.

Discussion
==========

The identification of serum AQP4 antibodies exclusively in patients with NMOSD clearly distinguished it from MS.[@b2] NMOSD-like lesions observed in experimental models with passive transfer or direct injection of AQP4 antibodies strongly suggest the pathogenicity of these autoantibodies.[@b11],[@b12] Astrocytes express AQP4, and their damage is evident with remarkable increase of GFAP in the CSF during NMOSD attacks.[@b6] Moreover, we previously reported that GFAP levels correlate with incapacity measured by expanded disability status scale and spinal cord lesion length. However, the serum AQP4 antibody titers usually do not correlate with GFAP levels,[@b6],[@b8] limiting the value of measuring AQP4 antibody titers during relapses in the serum. In this pilot study, we have shown that the amount of AQP4 antibody present directly in the CSF strongly correlates with astrocyte damage represented by elevated GFAP in the CSF, and this occurs together with signals of blood--brain barrier (BBB) breakdown and release of inflammatory cytokines. Elevation of IL-1β may promote BBB disruption,[@b13] other proinflammatory molecules are also increased in the CSF of NMOSD,[@b8],[@b14] and they may promote the recruitment of neutrophils and eosinophils found in acute NMOSD lesions.[@b4] We recognize that further studies including a larger number of patients with attack and remission samples are required to confirm these findings, but our results indicate that the AQP4 antibody levels found in the central nervous system (CNS) are a critical element to promote astrocyte injury in a dose-dependent manner.

BBB disruption correlated with CSF anti-AQP4 levels, and this may represent a significant source of AQP4 antibodies in the CSF during attacks. However, we cannot distinguish the AQP4 antibodies produced intrathecally in our study. Interestingly, we found that IL-6 and IL-10 correlated with AQP4 antibody levels in the CSF. IL-6 can promote B-cell survival, including IgG producing plasmablasts,[@b15] and IL-10 can promote maturation of memory B cells and immunoglobulin class switch.[@b16] Previous studies reported that B cells could migrate and differentiate to AQP4 antibody producing plasmablasts,[@b17],[@b18] so \>1 mechanism might be involved in the CSF AQP4 antibody levels. Patients treated with monoclonal antibodies blocking IL-6 receptor (tocilizumab) have a reduction in the number of circulating plasmablasts and experience a reduction in the number of attacks,[@b19] but it is unclear whether the drug effects have some extension into the CNS.

NMOSD attacks are usually severe and patients have a high risk of disability. Understanding the mechanisms that promote the BBB disruption and/or the migration of pathogenic memory B cells resulting in the presence of large amounts of AQP4 antibodies in the CNS can provide new therapeutic strategies to treat NMOSD patients in a more tailored approach with less of the risks and side effects found in B-cell depletion with rituximab, immunosuppressive drugs, and corticosteroids. Furthermore, strategies blocking the binding of pathogenic AQP4 antibodies to their antigen in the CNS[@b20] or preserving BBB integrity may reduce the astrocyte damage and permanent disability due to NMOSD attacks.
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